Snapshot from Jun 28, 2026 at 07:00 UTC. For live data and tracking: View Live
Person

Xia Yu

Tracked across 1 events · 7 articles · First seen Jun 12, 2026 · Last active Jun 12, 2026

Sentiment
0
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 0
Business
Akeso announced that the China — National Medical Products Administration of China has approved Gumokimab (AK111), its internally-developed anti-IL-17 monoclonal antibody, for the treatment of adult patients with moderate-to-severe plaque psoriasis. The approval was based…
Impact: Xia Yu, Founder, Chairwoman, President and CEO of Akeso, expressed gratitude to the study participants and highlighted Akeso's growing portfolio in autoimmune diseases.
Jun 12, 2026 · 7 articles
NEWSDESK
Track Xia Yu live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.